Back to Authors

Tobey, Danny

https://orcid.org/0009-0000-1611-2152

Mayo Clinic

DLA Piper, Los Angeles, CA, USA

Citations 3

A Collaborative Best Practice Guide for Promoting AI Vendor Transparency in Health Care — The HAIP AI Vendor Disclosure Framework
Kpodzro, Sena , Hasan, Alifia , Thomas, Ciera , Draugelis, Michael , Jeffries, Scott Morgan , Beecy, Ashley , Stroum, Corinne , Valladares, Alexandra , Eigen, Zev J. , Tobey, Danny , Vidal, David , Mulligan, Deirdre , Balu, Suresh , Kim, Jee Young , Lifson, Mark A. , Sendak, Mark

NEJM AI | April 23, 2026 | Volume: 3 | Issue: 5 | Pages: No page available

10.1056/aip2500985 Get It

Strengthening the use of artificial intelligence within healthcare delivery organizations: balancing regulatory compliance and patient safety
Sendak, Mark , Beecy, Ashley , Vidal, David , Shaw, Keo , Tobey, Danny , Valladares, Alexandra , Loufek, Brenna, Mogri, Murtaza, Balu, Suresh , Sendak, Mark P , Vidal, David E, Lifson, Mark A. , Liu, Vincent X.

Journal of the American Medical Informatics Association | May 9, 2024 | Volume: 31 | Issue: 7 | Pages: 1622-1627

10.1093/jamia/ocae119 Get It

Abstract Objectives Surface the urgent dilemma that healthcare delivery organizations (HDOs) face navigating the US Food and Drug Administration (FDA) final guidance on the use of clinical decision support (CDS) software. Materials and Methods We use sepsis as a case study to highlight the patient safety and regulatory compliance tradeoffs that 6129 hospitals in the United States must navigate. Results Sepsis CDS remains in broad, routine use. There is no commercially available sepsis CDS system that is FDA cleared as a medical device. There is no public disclosure of an HDO turning off sepsis CDS due to regulatory compliance concerns. And there is no public disclosure of FDA enforcement action against an HDO for using sepsis CDS that is not cleared as a medical device. Discussion and Conclusion We present multiple policy interventions that would relieve the current tension to enable HDOs to utilize artificial intelligence to improve patient care while also addressing FDA concerns about product safety, efficacy, and equity.
Organizational Governance of Emerging Technologies: AI Adoption in Healthcare
Kim, Jee Young , Boag, William , Gulamali, Freya , Hasan, Alifia , Hogg, Henry David Jeffry , Lifson, Mark A. , Mulligan, Deirdre K. , Patel, Manesh R. , Raji, Inioluwa Deborah , Sehgal, Ajai , Shaw, Keo , Tobey, Danny , Valladares, Alexandra , Vidal, David , Balu, Suresh , Sendak, Mark , Sehgal, Ajai , Sendak, Mark P , Lifson, Mark A , Mulligan, Deirdre

2023 ACM Conference on Fairness Accountability and Transparency | June 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1396-1417

10.1145/3593013.3594089 Get It